Peptide And Oligonucleotide CDMO Outlook 2034: Key Drivers, Trends, and Market Frontiers
Discover trends, market shifts, and competitive outlooks for the peptide and oligonucleotide cdmo industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Estimated Market Size of the Peptide And Oligonucleotide CDMO Market In 2029?
The market for peptides and oligonucleotides cdmo has seen a swift expansion in the past few years. The market, worth $2.16 billion in 2024, is expected to soar to $2.42 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.1%. The surge during the historical period can be linked to increased needs for therapeutic agents, progress in synthesis and manufacturing, and growing trends in personalized medicine. Additionally, regulatory guidelines, and a heightened emphasis on antiviral peptides and mRNA vaccines underscore the prominence of oligonucleotides in the development of vaccines.
Anticipated to experience swift expansion in the years to come, the peptide and oligonucleotide CDMO market is projected to escalate to $3.79 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. This predicted upsurge during the forecast period is largely due to factors such as the rising demand for tailor-made medicines, advancements in biotechnological field, broadening applications, the escalating tendency to outsource, and an increasing prevalence of chronic illnesses. Key trends during this projected period include personalized treatment modalities, enhancement in technology, challenges in maintaining quality, global market expansions, and heightened collaborative efforts among biopharmaceutical firms.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Peptide And Oligonucleotide CDMO Market?
As personalized medicine becomes more common, the peptide and oligonucleotide CDMO markets are set to experience substantial growth. Personalized medicine enables healthcare to be tailored according to individual factors, encompassing their genetics, environment, and lifestyle. The rise in popularity of this approach can be attributed to developments in genomic technology, a heightened comprehension of disease mechanisms on a molecular scale, and the call for more efficient and targeted treatment options that are adapted to suit the genetic profiles and medical backgrounds of individual patients. Crucial to this process are peptide and oligonucleotide contract development and manufacturing organizations (CDMOs), which create therapies meeting the unique needs of each patient. As an expression of this trend, in February 2024, the Personalized Medicine Coalition, a UK-based group advocating for the use of personalized medicine, reported that the FDA’s Center for Drug Evaluation and Research (CDER) had approved 16 novel personalized treatments for patients with rare diseases, a significant increase from the 6 approvals granted in 2022. This rise in personalized medicine’s use is therefore a driving factor behind the peptide and oligonucleotide CDMO market’s growth.
Which Segments in the Peptide And Oligonucleotide CDMO Offer the Most Growth?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp
Which Areas Are Leading Regions in the Peptide And Oligonucleotide CDMO Market Expansion Across the Globe?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Most Significant Market Trends in the Peptide And Oligonucleotide CDMO Market?
Leading firms engaged in the peptide and oligonucleotide CDMO market are concentrating on establishing strategic collaborations to augment their service portfolio, extend their technological prowess, and broaden their presence in the market. Partnerships concerning the development and manufacturing of peptides involves cooperative agreements between two companies centered around the manufacture and development of peptide-based treatments. For example, in May 2023, the American contract development and manufacturing organization (CDMO), PolyPeptide Group AG, forged a partnership with Numaferm GmbH, a biotech firm based in Germany, focusing on peptide production and development. The objective of this collaboration is to leverage PolyPeptide’s cGMP manufacturing capabilities and market penetration, in combination with Numaferm’s proficiency in environment-friendly peptide production and biochemical production platforms. The alliance aims to collaboratively investigate the evolution of suitable peptide candidates, with the intention of promoting more eco-friendly production of peptide-based APIs.
View the full report here:
What Are the Key Elements That Define the Peptide And Oligonucleotide CDMO Market?
A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that provides services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations offer expertise in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15892
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
